CTI BioPharma Corp (CTIC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:CTI BioPharma Corp (CTIC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9941
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company, which acquires, develops, and commercializes targeted therapies for a range of blood-related cancers. The company’s lead product, Pixuvri (pixantrone) is an aza-anthracenedione used for the treatment of multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) in adults. Its pipeline portfolio consists of Pacritinib for the treatment of myelofibrosis for all platelet counts, relapsed acute myeloid leukemia (AML), other hematological and solid tumor indications; and Tosedostat for AML and myelodysplastic syndrome. The company has subsidiaries in the UK and the US. CTI BioPharma is headquartered in Seattle, Washington, the US.

CTI BioPharma Corp (CTIC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CTI BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Cell Therapeutics Acquires Pacritinib From S*BIO 11
Venture Financing 13
CTI BioPharma Announces Venture Debt Financing 13
Licensing Agreements 14
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 14
Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 15
Equity Offering 17
CTI BioPharma to Raise up to USD50 Million in Public Offering of Shares 17
CTI BioPharma Raises USD69 Million in Public Offering of Shares 18
CTI BioPharma Raises USD45 Million in Public Offering of Series N-3 Preferred Stock 20
CTI BioPharma Raises USD55 Million in Public Offering of Series N-2 Preferred Stock 22
CTI BioPharma Raises USD50 Million in Public Offering of Shares 24
CTI BioPharma Raises USD15.7 Million in Private Placement of Shares 26
CTI BioPharma Raises USD35 Million in Public Offering of Preferred Shares 28
Cell Therapeutics Completes Private Placement Of Preferred Stock For US$15 Million 30
Cell Therapeutics Completes Public Offering Of Preferred Stock For US$60 Million 32
Cell Therapeutics Completes Second Tranche Of Private Placement Of Series 15-2 Convertible Preferred Stock For US$15 Million 34
CTI BioPharma Corp – Key Competitors 36
CTI BioPharma Corp – Key Employees 37
CTI BioPharma Corp – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Financial Announcements 39
Nov 01, 2018: CTI BioPharma reports third quarter 2018 financial results 39
Aug 02, 2018: CTI BioPharma reports second quarter 2018 financial results 40
May 03, 2018: CTI BioPharma Reports First Quarter 2018 Financial Results 42
Mar 07, 2018: CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results 43
Nov 06, 2017: CTI BioPharma Reports Third Quarter 2017 Financial Results 45
Aug 03, 2017: CTI BioPharma Reports Second Quarter 2017 Financial Results 46
May 03, 2017: CTI BioPharma Reports First Quarter 2017 Financial Results 47
Mar 02, 2017: CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results 48
Corporate Communications 50
Sep 26, 2017: CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions 50
Jul 24, 2017: CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors 51
Jun 05, 2017: CTI BioPharma Appoints David R. Parkinson, M.D., Leader in Oncology Clinical Development, to Board of Directors and Announces Board Member Resignations 52
Feb 27, 2017: CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO 53
Product News 54
01/09/2017: CTI BioPharma Announces Progress Of Pacritinib And Strategic Objectives For 2017 54
Product Approvals 56
Mar 24, 2017: Withdrawal of the marketing authorisation application for Enpaxiq (pacritinib) 56
Clinical Trials 57
Jan 05, 2017: CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib 57
Other Significant Developments 59
Jan 25, 2018: CTI BioPharma Provides Corporate and European Regulatory Update 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CTI BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CTI BioPharma Corp, Deals By Therapy Area, 2012 to YTD 2018 9
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cell Therapeutics Acquires Pacritinib From S*BIO 11
CTI BioPharma Announces Venture Debt Financing 13
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 14
Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 15
CTI BioPharma to Raise up to USD50 Million in Public Offering of Shares 17
CTI BioPharma Raises USD69 Million in Public Offering of Shares 18
CTI BioPharma Raises USD45 Million in Public Offering of Series N-3 Preferred Stock 20
CTI BioPharma Raises USD55 Million in Public Offering of Series N-2 Preferred Stock 22
CTI BioPharma Raises USD50 Million in Public Offering of Shares 24
CTI BioPharma Raises USD15.7 Million in Private Placement of Shares 26
CTI BioPharma Raises USD35 Million in Public Offering of Preferred Shares 28
Cell Therapeutics Completes Private Placement Of Preferred Stock For US$15 Million 30
Cell Therapeutics Completes Public Offering Of Preferred Stock For US$60 Million 32
Cell Therapeutics Completes Second Tranche Of Private Placement Of Series 15-2 Convertible Preferred Stock For US$15 Million 34
CTI BioPharma Corp, Key Competitors 36
CTI BioPharma Corp, Key Employees 37
CTI BioPharma Corp, Subsidiaries 38

List of Figures
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[CTI BioPharma Corp (CTIC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Halfords Group plc (HFD):企業の財務・戦略的SWOT分析
    Halfords Group plc (HFD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • PrIME Biologics Pte Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary PrIME Biologics Pte Ltd (PrIME Biologics) is a biotechnology company that develops and manufactures plasma products for human use. The company uses Preparative Isolation by Membrane Electrophoresis ((PrIME) technology, a disposable, fully-scalable and modular manufacturing process, to manufa …
  • Optus Inc:企業の戦略的SWOT分析
    Optus Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • American Eagle Outfitters Inc:戦略・SWOT・企業財務分析
    American Eagle Outfitters Inc - Strategy, SWOT and Corporate Finance Report Summary American Eagle Outfitters Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Telstra Corporation Ltd (TLS):企業の財務・戦略的SWOT分析
    Telstra Corporation Ltd (TLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Agios Pharmaceuticals Inc (AGIO):医療機器:M&Aディール及び事業提携情報
    Summary Agios Pharmaceuticals Inc (Agios) is a biopharmaceutical company that focuses on the discovery and development of investigational medicines for the treatment of cancer and rare genetic metabolic disorders. The company’s products include IDHIFA, an oral targeted inhibitor of the mutated IDH2 …
  • POSCO ICT Company Ltd. (022100):企業の財務・戦略的SWOT分析
    POSCO ICT Company Ltd. (022100) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Coro Mining Corp:企業の戦略・SWOT・財務情報
    Coro Mining Corp - Strategy, SWOT and Corporate Finance Report Summary Coro Mining Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Dana Inc:企業の戦略・SWOT・財務情報
    Dana Inc - Strategy, SWOT and Corporate Finance Report Summary Dana Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Norsk Hydro ASA (NHY)-エネルギー分野:企業M&A・提携分析
    Summary Norsk Hydro ASA (Hydro) is a global supplier of aluminum and an electricity producer. Its operations span the value chain, from bauxite extraction to the production of rolled and extruded aluminum products and building systems. Its portfolio of products include bauxite, alumina, extrusion in …
  • Dunmore Corporation:企業の戦略的SWOT分析
    Dunmore Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • National Fuel Gas Co (NFG):企業の財務・戦略的SWOT分析
    National Fuel Gas Co (NFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • The Cleveland Clinic Foundation:企業の戦略的SWOT分析
    The Cleveland Clinic Foundation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Mesa Air Group, Inc.:企業の戦略・SWOT・財務分析
    Mesa Air Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Mesa Air Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Akzo Nobel NV (AKZA):企業の財務・戦略的SWOT分析
    Akzo Nobel NV (AKZA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • NovImmune SA:製薬・医療:M&Aディール及び事業提携情報
    Summary NovImmune SA (NovImmune) is a biopharmaceutical company that discovers and develops antibody-based drugs for the treatment of inflammatory diseases, immune-related disorders and cancer. The company develops pipeline products using its proprietary mAb generating platform, DiversityTrap and ka …
  • LivePerson Inc (LPSN):企業の財務・戦略的SWOT分析
    LivePerson Inc (LPSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • SK Holdings Co Ltd (034730):企業の財務・戦略的SWOT分析
    SK Holdings Co Ltd (034730) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Kodiak Sciences Inc (KOD):製薬・医療:M&Aディール及び事業提携情報
    Summary Kodiak Sciences Inc (Kodiak Sciences), formerly Oligasis LLC is a drug development company that discovers new medicines for the healthcare sector. The company provides retinal medicines for treatment of wet and dry forms of age-related macular degeneration. It utilizes proprietary Bioconjuga …
  • Abivax SA (ABVX):製薬・医療:M&Aディール及び事業提携情報
    Summary Abivax SA (Abivax) is a biotechnology company that develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company’s pipeline products include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to induce f …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆